D. Boral Capital Initiates Coverage On Turn Therapeutics with Buy Rating, Announces Price Target of $8
Benzinga Newsdesk 10 months ago
NewsPrice TargetInitiationAnalyst Ratings
D. Boral Capital analyst Jason Kolbert initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $8.
D. Boral Capital analyst Jason Kolbert initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with a Buy rating and announces Price Target of $8.